Hinge Health Stretches Into Public Markets with Strong IPO Performance After Years of Private Growth
Hinge HealthHNGE brought pain relief to the masses — and maybe a fresh ache to short sellers last week. The digital health startup just raised $437M in its IPO, marking the first major telehealth debut in years — and reviving excitement in a sector that’s been nursing wounds since 2021.
When tech treats the pain: During COVID-19, several US telehealth players like AmwellAMWL and TeladocTDOC went public — only to stumble later amid overvaluation, waning demand, and post-pandemic operational hurdles. But Hinge Health seems to have cracked the code. Their secret? Automating nearly 95% of clinician hours with AI-powered tools eliminating the need for traditional hands-on therapy. CEO Daniel Perez believes healthcare automation is inevitable, stating, “At some point, whether 10, 50, or 200 years in the future, care delivery will be automated with technology.”
- More than 1.7B people worldwide suffer from musculoskeletal disorders, yet 73% skip in-person physical therapy due to transportation or scheduling barriers.
- Hinge Health solves the problem by tracking patient movements, adjusting treatment in real-time, and delivering 24/7 virtual therapist access straight to patients’ homes.
Is This Hinge Built to Last?
Although Hinge Health promises a new era in care delivery, its long-term profitability is still up for debate in the crowded digital health space. Its model revolves around selling to self-insured employers who want cost-effective healthcare benefits for workers. With 532K active members and access to nearly 20M people, the company’s growth trajectory looks promising. But scaling comes with a price — investments in AI development, clinical staffing, and customer acquisition could pressure margins as the platform branches into areas like women’s health and Medicare. Still, financial momentum is building:
- In Q1 2025, Hinge turned $17M in net income on $124M revenue — a turnaround from a $26M loss on $83M just a year earlier.
- That said, its current $2.6B valuation represents a 52% markdown from its 2021 private valuation peak of $6.2B.
The IPO unfreeze: Deloitte’s Will Braeutigam believes, “The investment community is thirsty again for IPOs,” particularly as smaller firms embrace the reality that they might face down rounds anyway — so it may make more sense to let public markets find the price instead. With theVIX dropping below 20 after April’s tariff-induced spike, conditions appear ripe for more small-cap debuts. So far in 2025, there have been 94 IPOs raising $12.9B, compared to 73 deals worth $16B during the same period last year — meaning more companies are going public, just at smaller valuations. Regardless, Hinge’s success could encourage other digital health firms like Omada Health, Sword Health, and Spring Health to test the public waters — assuming economic uncertainties don’t derail the momentum.